These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21180621)

  • 1. A review of the use of zonisamide in Parkinson's disease.
    Bermejo PE; Anciones B
    Ther Adv Neurol Disord; 2009 Sep; 2(5):313-7. PubMed ID: 21180621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zonisamide: in Parkinson's disease.
    Yang LP; Perry CM
    CNS Drugs; 2009 Aug; 23(8):703-11. PubMed ID: 19594199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zonisamide add-on in tremor-dominant Parkinson's disease- A randomized controlled clinical trial.
    Pillai KS; Bhat P; Srivastava AK; Rajan R; Radhakrishnan DM; Elavarasi A; Srivastava MP; Singh MB; Vishnu VY; Prasad K; Pandit AK; Goyal V
    Parkinsonism Relat Disord; 2022 Dec; 105():1-6. PubMed ID: 36323130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zonisamide add-on therapy for focal epilepsy.
    Brigo F; Lattanzi S; Igwe SC; Behzadifar M; Bragazzi NL
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD001416. PubMed ID: 32715463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zonisamide add-on therapy for focal epilepsy.
    Brigo F; Lattanzi S; Igwe SC; Behzadifar M; Bragazzi NL
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001416. PubMed ID: 30335200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide improves wearing-off in Parkinson's disease: A randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I; Fukasaka J; Kochi K; Shimazu R;
    Mov Disord; 2015 Sep; 30(10):1343-50. PubMed ID: 26094993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zonisamide: a new drug for Parkinson's disease.
    Murata M
    Drugs Today (Barc); 2010 Apr; 46(4):251-8. PubMed ID: 20502722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zonisamide for the Treatment of Parkinson Disease: A Current Update.
    Li C; Xue L; Liu Y; Yang Z; Chi S; Xie A
    Front Neurosci; 2020; 14():574652. PubMed ID: 33408605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson's Disease: A Meta-Analysis.
    Matsunaga S; Kishi T; Iwata N
    J Alzheimers Dis; 2017; 56(4):1229-1239. PubMed ID: 28157097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
    Murata M; Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K
    Parkinsonism Relat Disord; 2020 Jul; 76():91-97. PubMed ID: 31982288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zonisamide: review of its use in epilepsy therapy.
    Zareba G
    Drugs Today (Barc); 2005 Sep; 41(9):589-97. PubMed ID: 16341290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A; Benfield P
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zonisamide add-on for drug-resistant partial epilepsy.
    Carmichael K; Pulman J; Lakhan SE; Parikh P; Marson AG
    Cochrane Database Syst Rev; 2013 Dec; (12):CD001416. PubMed ID: 24353187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zonisamide for drug-resistant partial epilepsy.
    Chadwick DW; Marson AG
    Cochrane Database Syst Rev; 2000; (2):CD001416. PubMed ID: 10796786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zonisamide add-on for drug-resistant partial epilepsy.
    Chadwick DW; Marson AG
    Cochrane Database Syst Rev; 2002; (2):CD001416. PubMed ID: 12076409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zonisamide for the treatment of epilepsy.
    Arzimanoglou A; Rahbani A
    Expert Rev Neurother; 2006 Sep; 6(9):1283-92. PubMed ID: 17009916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic role of zonisamide in neuropsychiatric disorders.
    Farooq MU; Moore PW; Bhatt A; Aburashed R; Kassab MY
    Mini Rev Med Chem; 2008 Sep; 8(10):968-75. PubMed ID: 18782051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
    Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K; Murata M
    Am J Geriatr Psychiatry; 2022 Mar; 30(3):314-328. PubMed ID: 34420834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy.
    Peters DH; Sorkin EM
    Drugs; 1993 May; 45(5):760-87. PubMed ID: 7686468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.